

Poster session 3 & Ongoing trials 2 Thursday 5-7 PM

- P3-04-03** Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (*ERBB2*) mutations in metastatic breast cancer patients
Jongen L, Floris G, Lambrechts D, Laenen A, Neven P, Mann G, Cutler Jr. RE, Lalani AS, Wildiers H.
- P3-04-05** Outliers—extreme long-term survivors with metastatic breast cancer
Ejebe IH, Denu RA, Longhurst C, Bauman JD, MacGregor S, Lee K, Burkard ME.
- P3-05-07** Improving CAR T cell function by reversing the immunosuppressive tumor environment of breast cancer
Bajgain P, Tawinwung S, Watanabe N, Sukumaran S, Anurathapan U, Heslop HE, Rooney CM, Brenner M, Leen AM, Vera JF.
- P3-05-09** Prognostic factors for therapeutic personalized peptide vaccines in patients with metastatic recurrent breast cancer
Toh U, Saku S, Iwakuma N, Takao Y, Okabe M, Akashi M, Yamada A, Shichijo S, Itoh K, Akagi Y.
- P3-06-02** Tackling bone metastatic breast cancer growth with novel bone-seeking matrix metalloproteinase-2 inhibitors
Tauro M, Laghezza A, Tortorella P, Soliman HH, Lynch CC
- P3-06-09** Discovery of novel oridonin-derivatives for the treatment of metastatic breast cancer
Li D, Zhang Z, Ding Y, Zheng Z, Dong J, Kim H, Xu J, Chen H, Zhou J, Shen Q.
- P3-11-01** Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
Burstein HJ, Mayer EL, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M.
- P3-11-02** A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)
Nishimura R, Yamamoto Y, Narui K, Kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S,
- P3-11-03** The impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib
Clifton KK, Kimmel J, Yi M, Chad B, Litton J, Debu T, Meghan K
- P3-11-04** Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)
Gucalp A, Edelweiss M, Patil S, Gounder MM, Feigin KN, Corben A, Arumov A, Traina TA.
- P3-11-05** Everolimus-exemestane (EE) vs palbociclib-fulvestrant (PF) or abemaciclib-fulvestrant (AF) or everolimus-fulvestrant (EF) in the treatment of metastatic HR+, HER2- metastatic breast cancer and prior aromatase inhibitors treatment. An indirect comparison with network meta-analysis
Gianni L, Arcangeli V, Gianni C, Stocchi L, Menghini L, Samorani D, Ridolfi C, Emiliano T, Tassinari D.
- P3-11-06** A phase 1 study of KHK2375 (entinostat) as monotherapy and in combination with exemestane in Japanese patients with hormone receptor-positive, HER2-negative, advanced or recurrent breast cancer
Shimomura A, Masuda N, Tamura K, Yasojima H, Sawaki M, Nishimura Y, Saji S, Iwata H.
- P3-12-01** 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - "the Blissafe study"

Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Antolín-Novoa S, García-Estévez L, Bermejo de las Heras B, Presa-Lorite J, Sánchez-Vigil de la Villa I, Suárez-Almarza J, Nieto-Magro C

- P3-14-02** Incidence of venous thromboembolism in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials
Thein KZ, Zaw MH, Tun AM, Jones C, Radhi S, Hardwicke F, Oo TH.
- P3-14-06** The prevention and management of chemotherapy-induced peripheral neuropathy in breast cancer patients: A systematic review
Roberts KE, Feng S, Adsett I, Rickett K, Woodward N
- P3-15-02** Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: *2nd interim analysis*
Dent S, Califaretti N, Doyle C, Ferrario C, Chouinard E, Kulkarni S, Roy J-A, Perri SR, Chia S.
- P3-15-03** Clinical benefit, toxicity, and cost of metastatic breast cancer drug therapies: Visualizing randomized and non-randomized evidence
Silberholz J, Vahdat L, Bertsimas D.
- P3-17-02** Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E.
- P3-17-03** Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial
Bartlett CH, Mardekian J, Cotter M, Huang X, Zhang Z, Parrinello CM, Abernethy AP, Koehler M.

Ongoing trials 2

- OT2-01-05** Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)
Martín M, Kahan Z, Carrasco E, Bartlett CH Casas M, Gil-Gil M, Muñoz M, Ciruelos EM, Ruiz-Borrego M, Margelí M, Antón A, Bermejo B, Morales S, Gal-Yam E, Koehler M, García-Sáenz JA, de la Haba J, Chacón I, Zielinski C.
- OT2-05-01** A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
Gong C, Cao E, Wang Z, Zhang J, Wang L, Cao J, Zhang S, Tao Z, Li T, Zhao Y, Li Y, Wang B, Hu X.
- OT2-05-02** A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro
Schmidt M, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Möbus V.
- OT2-06-01** Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-Positive breast cancer brain metastases following stereotactic radiosurgery
Zimmer AS, Gril B, Steinberg S, Smart D, Gilbert M, Armstrong T, Xiao L, Houston N, Biassou N, Brastianos P, Carter S, Lyden DC, Lipkowitz S, Steeg P.
- OT2-06-02** A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)
Yamaguchi M, Nakayama T, Yoshinami T, Ikeda M, Iwamoto M, Komoike Y, Takashima T, Tsurutani J, Yoshidome K, Yamada T, Morita S, Masuda N.

- OT2-06-04** Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer
Anampa JD, Xue X, Oktay M, Condeelis J, Sparano JA.
- OT2-07-05** A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
Bardia A, Rugo HS, Horne H, Wegener WA, Goldenberg DM, O'Shaughnessy J.
- OT2-07-06** Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009)
Forero A, Han HS, Dees EC, Wesolowski R, Bardia A, Kabos P, Kern KA, Perea R, Pierce KJ, Houk B, Rugo HS.
- OT2-07-07** ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)
Telli ML, Lord S, Dean E, Abramson V, Arkenau H-T, Murias C, Becerra C, Tang R, Penney MS, Pollard J, Conboy G, Fields SZ, Shapiro G, Tolaney SM.
- OT2-07-10** ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
Tripathy D, Tolaney S, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves CJ, Diéras V, Müller V, Hannah A, Tagliaferri M, Cortés J.